Atara Biotherapeutics (ATRA) to Release Earnings on Monday

Key Points

• Atara Biotherapeutics is set to release its Q2 2025 earnings on Monday, August 11th, with analysts predicting a loss of ($0.32) per share and revenue of $4.23 million for the quarter.
• In its last earnings report from May 15th, the company posted an impressive $3.50 EPS, significantly exceeding expectations, with revenue of $98.10 million against forecasts of $4.30 million.
• Major shareholder Innovation Ltd Panacea increased their stake by purchasing 19,335 shares at $9.64 per share, bringing their total ownership to approximately 1.35 million shares valued at $13 million.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Atara Biotherapeutics to post earnings of ($0.32) per share and revenue of $4.23 million for the quarter.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The biotechnology company reported $3.50 EPS for the quarter, beating analysts' consensus estimates of ($3.07) by $6.57. The company had revenue of $98.10 million for the quarter, compared to analyst estimates of $4.30 million. On average, analysts expect Atara Biotherapeutics to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Atara Biotherapeutics Trading Down 0.0%

Shares of NASDAQ ATRA traded down $0.01 on Monday, reaching $11.55. 4,635 shares of the company traded hands, compared to its average volume of 117,206. Atara Biotherapeutics has a fifty-two week low of $5.01 and a fifty-two week high of $18.70. The company has a 50 day moving average of $9.16 and a 200 day moving average of $7.85. The stock has a market capitalization of $68.81 million, a PE ratio of -3.10 and a beta of 0.26.

Insider Transactions at Atara Biotherapeutics

In other Atara Biotherapeutics news, major shareholder Innovation Ltd Panacea bought 19,335 shares of the company's stock in a transaction that occurred on Thursday, July 17th. The stock was purchased at an average price of $9.64 per share, with a total value of $186,389.40. Following the transaction, the insider owned 1,350,000 shares in the company, valued at $13,014,000. This trade represents a 1.45% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 4.00% of the company's stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.